Filing Details

Accession Number:
0001209191-21-026666
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-04-14 16:43:36
Reporting Period:
2021-04-12
Accepted Time:
2021-04-14 16:43:36
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1664710 Keros Therapeutics Inc. KROS Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1808322 Jennifer Lachey C/O Keros Therapeutics, Inc.
99 Hayden Avenue, Suite 120, Building E
Lexington MA 02421
Chief Scientific Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-04-12 5,300 $0.30 76,487 No 4 M Direct
Common Stock Disposition 2021-04-12 998 $59.10 75,489 No 4 S Direct
Common Stock Disposition 2021-04-12 3,473 $59.99 72,016 No 4 S Direct
Common Stock Disposition 2021-04-12 729 $61.08 71,287 No 4 S Direct
Common Stock Disposition 2021-04-12 100 $61.72 71,187 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (right to buy) Disposition 2021-04-12 5,300 $0.00 5,300 $0.30
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
135,005 2028-03-25 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.54 to $59.52 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5).
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.55 to $60.43 inclusive.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.58 to $61.535 inclusive.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.625 to $61.725 inclusive
  6. Immediately exercisable.